©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 24, 2016; 6(2): 321-330
Published online Jun 24, 2016. doi: 10.5500/wjt.v6.i2.321
Published online Jun 24, 2016. doi: 10.5500/wjt.v6.i2.321
First line vs delayed transplantation in myeloma: Certainties and controversies
Annamaria Brioli, Klinik für Innere Medizin II (Abteilung Hämatologie und internistische Onkologie), Universitätsklinikum Jena, 07740 Jena, Germany
Annamaria Brioli, Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy
Author contributions: Brioli A performed bibliographical research and wrote the paper.
Conflict-of-interest statement: The author declares no conflicts of interests.
Correspondence to: Annamaria Brioli, MD, PhD, Klinik für Innere Medizin II (Abteilung Hämatologie und internistische Onkologie), Universitätsklinikum Jena, Erlanger Allee 101, 07740 Jena, Germany. annamaria.brioli2@unibo.it
Telephone: +49-03641-9349576
Received: June 28, 2015
Peer-review started: July 5, 2015
First decision: September 17, 2015
Revised: March 22, 2016
Accepted: April 7, 2016
Article in press: April 11, 2016
Published online: June 24, 2016
Processing time: 359 Days and 18.6 Hours
Peer-review started: July 5, 2015
First decision: September 17, 2015
Revised: March 22, 2016
Accepted: April 7, 2016
Article in press: April 11, 2016
Published online: June 24, 2016
Processing time: 359 Days and 18.6 Hours
Core Tip
Core tip: Autologous stem cell transplantation (ASCT) is the cornerstone for the treatment of young multiple myeloma patients. This review summarizes the current knowledge on ASCT, with a special focus on the role of ASCT in the era of novel agents for multiple myeloma treatment.